Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Francesca Marrocolo"'
Autor:
Maristella Canovai, Monica Evangelista, Alberto Mercatanti, Romina D’Aurizio, Letizia Pitto, Francesca Marrocolo, Valentina Casieri, Marco Pellegrini, Vincenzo Lionetti, Sergio Bracarda, Milena Rizzo
Publikováno v:
Cell Death Discovery, Vol 9, Iss 1, Pp 1-13 (2023)
Abstract Docetaxel (DCT) resistance is one of the main factors responsible for treatment failure in metastatic prostate cancer (PCa). Although several mechanisms of DCT resistance have been elucidated, the issue is still far from comprehensive. In th
Externí odkaz:
https://doaj.org/article/e8ec5241ae5d4922884fe0067fd7303a
Autor:
Lorenzo Bascetta, Monica Evangelista, Arianna Oliviero, Francesca Marrocolo, Marco Pellegrini, Sergio Bracarda, Milena Rizzo, Romina D'Aurizio, Alberto Mercatanti
Publikováno v:
International Journal of Molecular Sciences; Volume 18; Issue 7; Pages: 1512
International Journal of Molecular Sciences, Vol 18, Iss 7, p 1512 (2017)
International journal of molecular sciences (Online) 18 (2017). doi:10.3390/ijms18071512
info:cnr-pdr/source/autori:Bascetta L., Oliviero A., D'Aurizio R., Evangelista M., Mercatanti A., Pellegrini M., Marrocolo F., Bracarda S., Rizzo M./titolo:The prostate cancer cells resistant to docetaxel as in vitro model for discovering micrornas predictive of the onset of docetaxel resistance/doi:10.3390%2Fijms18071512/rivista:International journal of molecular sciences (Online)/anno:2017/pagina_da:/pagina_a:/intervallo_pagine:/volume:18
International Journal of Molecular Sciences
International Journal of Molecular Sciences, Vol 18, Iss 7, p 1512 (2017)
International journal of molecular sciences (Online) 18 (2017). doi:10.3390/ijms18071512
info:cnr-pdr/source/autori:Bascetta L., Oliviero A., D'Aurizio R., Evangelista M., Mercatanti A., Pellegrini M., Marrocolo F., Bracarda S., Rizzo M./titolo:The prostate cancer cells resistant to docetaxel as in vitro model for discovering micrornas predictive of the onset of docetaxel resistance/doi:10.3390%2Fijms18071512/rivista:International journal of molecular sciences (Online)/anno:2017/pagina_da:/pagina_a:/intervallo_pagine:/volume:18
International Journal of Molecular Sciences
On the grounds that miRNAs present in the blood of prostate cancer (PCa) patients are released in the growth medium by PCa cells, it is conceivable that PCa cells resistant to docetaxel (DCT) (DCTR) will release miRNAs that may be found in PCa patien
Autor:
Alketa Hamzaj, Sergio Bracarda, Michele Sisani, Sabrina Del Buono, Francesca Marrocolo, Amelia Altavilla
Publikováno v:
Expert Review of Anticancer Therapy. 14:1283-1294
Although docetaxel is still considered a mainstay of treatment in metastatic castrate-resistant prostate cancer (mCRPC), in the last few years, new agents have been developed to improve survival in this setting and reach a possible optimal personaliz
Autor:
Alketa Hamzaj, Francesca Marrocolo, Valeria Simone, Sabrina Del Buono, Michele Sisani, Sergio Bracarda
Publikováno v:
Critical reviews in oncology/hematology. 89(3)
Metastatic renal cell carcinoma (mRCC), considered almost an orphan disease only six years ago, appears today a very dynamic pathology. The recently switch to the actual overcrowded scenario defined by seven active drugs has driven physicians to an i
Publikováno v:
I supplementi di Tumori : official journal of Societa italiana di cancerologia ... [et al.]. 3(4)
Autor:
Maurizio Tonato, Sergio Ricci, Luca Galli, Andrea Antonuzzo, Giorgio V. Scagliotti, Lucio Crinò, Silvia Novello, Giovanni Selvaggi, S. Darwish, Sara Sorbolini, Ernesto Pozzi, Francesca Marrocolo
Introduction: This phase II study was designed to assess the activity and tolerability of the carboplatin–paclitaxel combination, given without routine growth factor support to previously untreated patients with stage IIIB and IV non-small cell lun
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::754d01bf81b49c6d69e497cdbb2d6e76
http://hdl.handle.net/2318/1691301
http://hdl.handle.net/2318/1691301
Autor:
Francesca Marrocolo, Alketa Hamzaj, Sergio Bracarda, Sabrina Del Buono, Michele Sisani, Giuseppe Di Lorenzo, Valeria de Simone, Verena De Angelis
Publikováno v:
Journal of Clinical Oncology. 31:e16093-e16093
e16093 Background: in recent years Abiraterone Acetate (AA) andCabazitaxel (Cbz) were shown to be efficacious agents in patients with mDR-CRPC. However, no data exist for patients treated with both these drugs in terms of best sequencing evaluation a
Autor:
Sergio Bracarda, Michele Sisani, Alketa Hamzaj, V. De Angelis, S. Del Buono, Francesca Marrocolo
Publikováno v:
Annals of Oncology. 23:ix315
Purpose In recent years both cabazitaxel (Cbz) and abiraterone acetate (AA) showed to be efficacious treatment options for patients with mDR-CRPC. However, no data exist for patients treated with both these drugs. Aim of our study was to analyze thes